Clearside Biomedical's Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal Delivery
Stock Information for Clearside Biomedical Inc.
Loading
Please wait while we load your information from QuoteMedia.